Print Page  Close Window

Investor Relations

DGX (Common Stock)
ExchangeNYSE (US Dollar)
Price$103.23
Change (%) Stock is Down 0.34 (0.33%)
Intraday High$103.37
Intraday Low$102.14
Volume246,219
Data as of 01/23/18 2:09 p.m. ET
Minimum 20 minute delay
Refresh quote
Headlines More >
TitleDate
Quest Diagnostics to Acquire MedXM, Expanding its Health Risk Assessment Services to Close Gaps in Care
Acquisition to strengthen Quest's mobile provider capabilities and population health management solutions for health plans SECAUCUS, N.J., Jan. 23, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has formed a definitive agreement to acquire Mobile Medical Examination Service (MedXM), a leading national provider of home-based health risk assessments and related services. ... 
01/23/18
Quest Diagnostics To Release Fourth Quarter And Full Year 2017 Financial Results On February 1
SECAUCUS, N.J., Jan. 19, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2017 results on Thursday, February 1, 2018, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.  The conference call can be accessed in listen-only mode by dia... 
01/19/18
Quest Diagnostics Named One of 2018 "World's Most Admired Companies" by Fortune Magazine for Third Consecutive Year
SECAUCUS, N.J., Jan. 19, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" for 2018 by Fortune for the third consecutive year.  The annual survey designated Quest Diagnostics as one of only five companies in the "Health Care: Pharmacy and Other Services" industry to attain Most Admired status.  The company advan... 
01/19/18
Quest Diagnostics To Speak At The 36th Annual J.P. Morgan Healthcare Conference
SECAUCUS, N.J., Jan. 3, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, Chairman, President and CEO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence.  The presentation is scheduled for Wednesday, January 10, 2018 at 12:... 
01/03/18
Upcoming EventsMore >
DateTitle
02/01/18 08:30:00 ET
Q4 2017 Quest Diagnostics Earnings Conference Call
Contact Us:
Shawn Bevec
Executive Director Investor Relations
973-520-2900
Investor@QuestDiagnostics.com

Company Calendar
January 2018?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-11234
01/04/18
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
56
78910111213
14151617181920
21222324252627
28293031515253

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.